1. Home
  2. SFHG vs TSHA Comparison

SFHG vs TSHA Comparison

Compare SFHG & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SFHG

Samfine Creation Holdings Group Limited Ordinary Share

HOLD

Current Price

$2.48

Market Cap

16.2M

ML Signal

HOLD

Logo Taysha Gene Therapies Inc.

TSHA

Taysha Gene Therapies Inc.

HOLD

Current Price

$6.79

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SFHG
TSHA
Founded
1993
2019
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Publishing
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.2M
1.8B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
SFHG
TSHA
Price
$2.48
$6.79
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$11.63
AVG Volume (30 Days)
10.7K
2.6M
Earning Date
10-30-2025
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
5.56
EPS
N/A
N/A
Revenue
N/A
$9,773,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$1,152.42
P/E Ratio
N/A
N/A
Revenue Growth
N/A
17.28
52 Week Low
$0.32
$2.25
52 Week High
$3.17
$7.30

Technical Indicators

Market Signals
Indicator
SFHG
TSHA
Relative Strength Index (RSI) 53.20 66.11
Support Level $2.34 $4.39
Resistance Level $2.60 $7.30
Average True Range (ATR) 0.12 0.39
MACD -0.01 -0.03
Stochastic Oscillator 66.66 60.92

Price Performance

Historical Comparison
SFHG
TSHA

About SFHG Samfine Creation Holdings Group Limited Ordinary Share

Samfine Creation Holdings Group Ltd operates through its subsidiaries. It is an established one-stop printing service provider which principally provides printing services in Hong Kong and the PRC. It offers a wide range of printed products such as (i) book products, which mainly include children's books, educational books, art books, notebooks, diaries and journals; and (ii) novelty and packaging products, which mainly include handcraft products, book sets, pop-up books, stationery products, products with assembly parts and other specialized products, shopping bags and package boxes.

About TSHA Taysha Gene Therapies Inc.

Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.

Share on Social Networks: